Results 121 to 130 of about 59,014 (262)

Pulmonary Paragonimiasis Presenting as Pneumothorax, Hemoptysis, and Severe Eosinophilia: A Case Report. [PDF]

Case Rep Infect Dis
Basnet A, Sankhi MN, Pant C, Vashisht R, Singh A, Gurung B, Kunwor B.   +6 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Acquired Platelet Dysfunction with Eosinophilia: A Narrative Review. [PDF]

Pediatr Rep
Lee AC.
europepmc   +1 more source

Case Report: A case of non-secretory multiple myeloma presenting with eosinophilia: diagnostic challenges and a focused literature review. [PDF]

Front Oncol
Zhong J, Liu X, Liu J, Xiao S, Gu X, Liu Z.   +5 more
europepmc   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Hypereosinophilia of persistent/unknown cause: a bone marrow-based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing. [PDF]

Am J Clin Pathol
Eletrebi MM, Sanchez-Ramirez J, Abdalla A, Holman CJ.   +3 more
europepmc   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

Benralizumab as a steroid-sparing rescue therapy in ANCA-negative eosinophilic granulomatosis with polyangiitis: real-world experience from three cases and review of the literature. [PDF]

Rheumatol Int
Sebastian A, Kosałka-Węgiel J, Puchala M, Życińska K, Kolarz B, Bieniasz-Pawlik E, Korkosz M.   +6 more
europepmc   +1 more source

Hodgkin lymphoma with hypereosinophilia in a pediatric patient: case report and review of the literature. [PDF]

Front Pediatr
Cruz Osorio RM, Navarro-Martin Del Campo RM, Carrasco-Rivera WC, Bruijnzeels-Ponce LP, Gutiérrez-Ortiz JA, Quintero-Buenrostro H, Salceda-Rivera V, Martinez-Albarran MD, Ugalde-Aviña D, Soto Chavez V, Sánchez-Zubieta F, Gonzalez-Ramella O.   +11 more
europepmc   +1 more source

Patch Testing in Paediatric Drug Hypersensitivity Reactions: Current Evidence and Clinical Implications

Contact Dermatitis, EarlyView.
ABSTRACT Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis.
Gabriele Simonetti, Francesco Catamerò, Giulia Liccioli, Leonardo Tomei, Simona Barni, Mattia Giovannini, Lucrezia Sarti, Francesca Mori   +7 more
wiley   +1 more source